{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreierjsw2in33m2iytfipifbxv3v7joytegvojetdfdk75kfytvi3oq",
    "uri": "at://did:plc:svcthvzunxmjidtlw23zva6n/app.bsky.feed.post/3mhhk7wgpp6q2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreigqu5dqpelmek53vbcfbfu2m2zkswnybejqdmnibjjwqseqfmy7fu"
    },
    "mimeType": "image/jpeg",
    "size": 7820
  },
  "path": "/2026/03/20/gi-innovation-announces-first-clinical-supply-agreement-to-explore-combination-therapy-for-prostate-cancer/",
  "publishedAt": "2026-03-20T01:29:00.000Z",
  "site": "https://laotiantimes.com",
  "tags": [
    "Cision PR Newswire"
  ],
  "textContent": "SEOUL, South Korea, March 20, 2026 /PRNewswire/ — GI Innovation announced on 19th that it has entered into a clinical supply agreement with Johnson & Johnson to evaluate a combination therapy in patients with metastatic castration-resistant prostate cancer (mCRPC) in a phase 1b clinical trial. GI Innovation Announces First Clinical Supply Agreement to Explore Combination […]",
  "title": "GI Innovation Announces First Clinical Supply Agreement to Explore Combination Therapy for Prostate Cancer"
}